Rosiglitazone enhances the radiosensitivity of p53-mutant HT-29 human colorectal cancer cells

Biochemical and Biophysical Research Communications

Volumn 394, Issue 3, 2010, Pages 774-779

  Chiu, Shu Jun ^a,b   Hsaio, Ching Hui ^a   Tseng, Ho Hsing ^a   Su, Yu Han ^a   Shih, Wen Ling ^c   Lee, Jeng Woei ^a   Chuah, Jennifer Qiu Yu ^a  

^a TZU CHI UNIVERSITY   (Taiwan)

^b TZU CHI COLLEGE OF TECHNOLOGY   (Taiwan)

^c NATIONAL PINGTUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Human colorectal cancer cells; Radiosensitivity; Rosiglitazone

Indexed keywords

BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; CASPASE 3; CASPASE 8; CASPASE 9; HISTONE H2AX; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN KINASE B; PROTEIN P53; RADIOSENSITIZING AGENT; ROSIGLITAZONE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER RADIOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL STRAIN HT29; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DNA DAMAGE; HUMAN; HUMAN CELL; METASTASIS INHIBITION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY;

APOPTOSIS; CELL CYCLE; CELL SURVIVAL; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HISTONES; HT29 CELLS; HUMANS; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTO-ONCOGENE PROTEINS C-AKT; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; THIAZOLIDINEDIONES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77950519411     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.03.068     Document Type: Article

References (36)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., and Thun M.J. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
2. Saltz L.B., and Minsky B. Adjuvant therapy of cancers of the colon and rectum. Surg. Clin. North Am. 82 (2002) 1035-1058
3. Xu Y. Induction of genetic instability by gain-of-function p53 cancer mutants. Oncogene 27 (2008) 3501-3507
4. Seiwert T.Y., Salama J.K., and Vokes E.E. The concurrent chemoradiation paradigm-general principles. Nat. Clin. Pract. Oncol. 4 (2007) 86-100
5. Blanquicett C., Roman J., and Hart C.M. Thiazolidinediones as anti-cancer agents. Cancer Ther. 6 (2008) 25-34
6. Sheu W.H., Ou H.C., Chou F.P., Lin T.M., and Yang C.H. Rosiglitazone inhibits endothelial proliferation and angiogenesis. Life Sci. 78 (2006) 1520-1528
7. Magenta G., Borenstein X., Rolando R., and Jasnis M.A. Rosiglitazone inhibits metastasis development of a murine mammary tumor cell line LMM3. BMC Cancer 8 (2008) 47
8. Girnun G.D., Chen L., Silvaggi J., Drapkin R., Chirieac L.R., Padera R.F., Upadhyay R., Vafai S.B., Weissleder R., Mahmood U., Naseri E., Buckley S., Li D., Force J., McNamara K., Demetri G., Spiegelman B.M., and Wong K.K. Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. Clin. Cancer Res. 14 (2008) 6478-6486
9. Zhang Y.Q., Tang X.Q., Sun L., Dong L., Qin Y., Liu H.Q., Xia H., and Cao J.G. Rosiglitazone enhances fluorouracil-induced apoptosis of HT-29 cells by activating peroxisome proliferator-activated receptor gamma. World J. Gastroenterol. 13 (2007) 1534-1540
10. Kim Y.H., Jung E.M., Lee T.J., Kim S.H., Choi Y.H., Park J.W., Choi K.S., and Kwon T.K. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP. Free Radic. Biol. Med. 44 (2008) 1055-1068
11. Lu M., Kwan T., Yu C., Chen F., Freedman B., Schafer J.M., Lee E.J., Jameson J.L., Jordan V.C., and Cryns V.L. Peroxisome proliferator-activated receptor gamma agonists promote TRAIL-induced apoptosis by reducing survivin levels via cyclin D3 repression and cell cycle arrest. J. Biol. Chem. 280 (2005) 6742-6751
12. Chen W.C., Lin M.S., and Bai X. Induction of apoptosis in colorectal cancer cells by peroxisome proliferators-activated receptor gamma activation up-regulating PTEN and inhibiting PI3K activity. Chin. Med. J. (Engl.) 118 (2005) 1477-1481
13. Yang F.G., Zhang Z.W., Xin D.Q., Shi C.J., Wu J.P., Guo Y.L., and Guan Y.F. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines. Acta Pharmacol. Sin. 26 (2005) 753-761
14. Fuhrman C.B., Kilgore J., LaCoursiere Y.D., Lee C.M., Milash B.A., Soisson A.P., and Zempolich K.A. Radiosensitization of cervical cancer cells via double-strand DNA break repair inhibition. Gynecol. Oncol. 110 (2008) 93-98
15. Tanaka T., Munshi A., Brooks C., Liu J., Hobbs M.L., and Meyn R.E. Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity. Clin. Cancer Res. 14 (2008) 1266-1273
16. Maggiorella L., Deutsch E., Frascogna V., Chavaudra N., Jeanson L., Milliat F., Eschwege F., and Bourhis J. Enhancement of radiation response by roscovitine in human breast carcinoma in vitro and in vivo. Cancer Res. 63 (2003) 2513-2517
17. Rogakou E.P., Pilch D.R., Orr A.H., Ivanova V.S., and Bonner W.M. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J. Biol. Chem. 273 (1998) 5858-5868
18. Chiu S.J., Chao J.I., Lee Y.J., and Hsu T.S. Regulation of gamma-H2AX and securin contribute to apoptosis by oxaliplatin via a p38 mitogen-activated protein kinase-dependent pathway in human colorectal cancer cells. Toxicol. Lett. 179 (2008) 63-70
19. Downey M., and Durocher D. gammaH2AX as a checkpoint maintenance signal. Cell Cycle 5 (2006) 1376-1381
20. Keogh M.C., Kim J.A., Downey M., Fillingham J., Chowdhury D., Harrison J.C., Onishi M., Datta N., Galicia S., Emili A., Lieberman J., Shen X., Buratowski S., Haber J.E., Durocher D., Greenblatt J.F., and Krogan N.J. A phosphatase complex that dephosphorylates gammaH2AX regulates DNA damage checkpoint recovery. Nature 439 (2006) 497-501
21. Valerie K., Yacoub A., Hagan M.P., Curiel D.T., Fisher P.B., Grant S., and Dent P. Radiation-induced cell signaling: inside-out and outside-in. Mol. Cancer Ther. 6 (2007) 789-801
22. Li H.F., Kim J.S., and Waldman T. Radiation-induced Akt activation modulates radioresistance in human glioblastoma cells. Radiat. Oncol. 4 (2009) 43
23. Schuurbiers O.C., Kaanders J.H., van der Heijden H.F., Dekhuijzen R.P., Oyen W.J., and Bussink J. The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. J. Thorac. Oncol. 4 (2009) 761-767
24. Engelman J.A., Luo J., and Cantley L.C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7 (2006) 606-619
25. Dent P., Yacoub A., Fisher P.B., Hagan M.P., and Grant S. MAPK pathways in radiation responses. Oncogene 22 (2003) 5885-5896
26. Amorino G.P., Mikkelsen R.B., Valerie K., and Schmidt-Ullrich R.K. Dominant-negative cAMP-responsive element-binding protein inhibits proliferating cell nuclear antigen and DNA repair leading to increased cellular radiosensitivity. J. Biol. Chem. 278 (2003) 29394-29399
27. Pawlik T.M., and Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 59 (2004) 928-942
28. Bonner W.M., Redon C.E., Dickey J.S., Nakamura A.J., Sedelnikova O.A., Solier S., and Pommier Y. GammaH2AX and cancer. Nat. Rev. Cancer 8 (2008) 957-967
29. Mody M., Dharker N., Bloomston M., Wang P.S., Chou F.S., Glickman T.S., McCaffrey T., Yang Z., Pumfery A., Lee D., Ringel M.D., and Pinzone J.J. Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202. Endocr. Relat. Cancer 14 (2007) 305-315
30. Wu J.S., Lin T.N., and Wu K.K. Rosiglitazone and PPAR-gamma overexpression protect mitochondrial membrane potential and prevent apoptosis by upregulating anti-apoptotic Bcl-2 family proteins. J. Cell. Physiol. 220 (2009) 58-71
31. Wu J.S., Cheung W.M., Tsai Y.S., Chen Y.T., Fong W.H., Tsai H.D., Chen Y.C., Liou J.Y., Shyue S.K., Chen J.J., Chen Y.E., Maeda N., Wu K.K., and Lin T.N. Ligand-activated peroxisome proliferator-activated receptor-gamma protects against ischemic cerebral infarction and neuronal apoptosis by 14-3-3 epsilon upregulation. Circulation 119 (2009) 1124-1134
32. Ries S., Biederer C., Woods D., Shifman O., Shirasawa S., Sasazuki T., McMahon M., Oren M., and McCormick F. Opposing effects of Ras on p53: transcriptional activation of mdm2 and induction of p19ARF. Cell 103 (2000) 321-330
33. Shonai T., Adachi M., Sakata K., Takekawa M., Endo T., Imai K., and Hareyama M. MEK/ERK pathway protects ionizing radiation-induced loss of mitochondrial membrane potential and cell death in lymphocytic leukemia cells. Cell Death Differ. 9 (2002) 963-971
34. Park H.S., Yun Y., Kim C.S., Yang K.H., Jeong M., Ahn S.K., Jin Y.W., and Nam S.Y. A critical role for AKT activation in protecting cells from ionizing radiation-induced apoptosis and the regulation of acinus gene expression. Eur. J. Cell. Biol. 88 (2009) 563-575
35. Cao L.Q., Chen X.L., Wang Q., Huang X.H., Zhen M.C., Zhang L.J., Li W., and Bi J. Upregulation of PTEN involved in rosiglitazone-induced apoptosis in human hepatocellular carcinoma cells. Acta Pharmacol. Sin. 28 (2007) 879-887
36. Gupta A.K., Cerniglia G.J., Mick R., Ahmed M.S., Bakanauskas V.J., Muschel R.J., and McKenna W.G. Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002. Int. J. Radiat. Oncol. Biol. Phys. 56 (2003) 846-853